Negotiating prices for new cancer drugs could be bad for patients, payers, investors. An Amazon MTurk experiment shows: the negotiation setting itself has a noteworthy impact. 61% of patients were not given access to a new treatment. Still, 20% of assets were redistributed from payers to investors. User nachtwurm, in the Reddit Science subreddit, 15 Jun 2020